Pyronaridine

Pyronaridine is an antimalarial drug.[1] It was first made in 1970 and has been in clinical use in China since the 1980s.[2]

Pyronaridine
Clinical data
Other namesPyronaridine tetraphosphate
Routes of
administration
Oral, intramuscular injection, intravenous therapy
ATC code
  • none
Legal status
Legal status
  • CLP (EU): Acute Tox. 3(H301), Eye Dam. 1 (H318), Repr. 2 (H361), Aquatic Chronic 4 (H413)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC29H32ClN5O2
Molar mass518.06 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

It is one of the components of the artemisinin combination therapy pyronaridine/artesunate (Pyramax).[3]

It has also been studied as a potential anticancer drug.[4]

References

  1. Croft, Simon L.; Duparc, Stephan; Arbe-Barnes, Sarah J.; Craft, J.; Shin, Chang-Sik; Fleckenstein, Lawrence; Borghini-Fuhrer, Isabelle; Rim, Han-Jong (2012). "Review of pyronaridine anti-malarial properties and product characteristics". Malaria Journal. 11: 270. doi:10.1186/1475-2875-11-270. PMC 3483207. PMID 22877082.
  2. Chang C, Lin-Hua T, Jantanavivat C (1992). "Studies on a new antimalarial compound: pyronaridine". Trans R Soc Trop Med Hyg. 86 (1): 7–10. doi:10.1016/0035-9203(92)90414-8. PMID 1566313.
  3. "Pyramax" (PDF). European Medicines Agency. 2016.
  4. Villanueva, Paulina J.; Martinez, Alberto; Baca, Sarah T.; Dejesus, Rebecca E.; Larragoity, Manuel; Contreras, Lisett; Gutierrez, Denisse A.; Varela-Ramirez, Armando; Aguilera, Renato J. (2018). "Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis". PLOS ONE. 13 (11): e0206467. doi:10.1371/journal.pone.0206467. PMC 6218039. PMID 30395606.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.